Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

NCT02392468 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Alzheimer Disease

Interventions

DRUG: Placebo matching BI 409306 25 mg
DRUG: Placebo matching BI 409306 50 mg
DRUG: BI 409306 25 mg
DRUG: BI 409306 50 mg

Sponsor

Boehringer Ingelheim